There are 2949 resources available
Welcome and introduction
Presenter: Karim Fizazi
Session: F. Hoffmann-La Roche - Reshaping treatment paradigms for GU cancer patients: Perspectives on PI3K/AKT inhibitors in mCRPC and immunotherapy in urothelial cancer
Resources:
Webcast
Improving outcomes with immunotherapy in urothelial cancer: Perspectives on the latest data
Presenter: Enrique Grande
Session: F. Hoffmann-La Roche - Reshaping treatment paradigms for GU cancer patients: Perspectives on PI3K/AKT inhibitors in mCRPC and immunotherapy in urothelial cancer
Resources:
Webcast
The changing landscape of metastatic prostate cancer: Challenges and evolving opportunities
Presenter: Karim Fizazi
Session: F. Hoffmann-La Roche - Reshaping treatment paradigms for GU cancer patients: Perspectives on PI3K/AKT inhibitors in mCRPC and immunotherapy in urothelial cancer
Resources:
Webcast
Targeting AKT: Next breaAKThrough therapies for prostate cancer care?
Presenter: Johann de Bono
Session: F. Hoffmann-La Roche - Reshaping treatment paradigms for GU cancer patients: Perspectives on PI3K/AKT inhibitors in mCRPC and immunotherapy in urothelial cancer
Resources:
Webcast
Predictors of treatment outcomes in patients with advanced ovarian cancer
Presenter: Bradley Monk
Session: GSK - Treatment options for women with advanced ovarian cancer: Evaluating the evidence
Resources:
Webcast
Evaluating first-line maintenance therapy options
Presenter: Antonio González Martín
Session: GSK - Treatment options for women with advanced ovarian cancer: Evaluating the evidence
Resources:
Webcast
The role of genetic testing in the treatment decision-making process
Presenter: Kathleen Moore
Session: GSK - Treatment options for women with advanced ovarian cancer: Evaluating the evidence
Resources:
Webcast
PARPi in the treatment of recurrent disease
Presenter: Jonathan Ledermann
Session: GSK - Treatment options for women with advanced ovarian cancer: Evaluating the evidence
Resources:
Webcast
Chair’s welcome and introductions
Presenter: Neal Shore
Session: AstraZeneca - PARP inhibitors in the treatment of metastatic castrate resistant prostate cancer
Resources:
Webcast
Exploring molecular heterogeneity in prostate cancer - prevalence and clinical significance
Presenter: Neal Shore
Session: AstraZeneca - PARP inhibitors in the treatment of metastatic castrate resistant prostate cancer
Resources:
Webcast